Please assess the completion status of the following clinical trial:

Trial Title: HD12 for Advanced Stages

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Hodgkin´s lymphoma (histologically proven)~* CS(PS) IIB with one or both of the risk factors:~  1. bulky mediastinal mass (\> 1/3 of maximum transverse thorax diameter)~ 2. extranodal involvement~* CS(PS) III, IV~* written informaed consent~Exclusion Criteria:~* Leukocytes \<3000/microl~* Platelets \<100000/microl~* Hodgkin´s Disease as composite lymphoma~* Activity index (WHO) \< grade 2

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).